Cell-compressing technique a new path in immunotherapy

November 1, 2018 by Zach Winn, Massachusetts Institute of Technology
To engineer cell functions, SQZ Biotech uses tiny channels on a microfluidic chip to squeeze cells so they can be penetrated by specific molecules. Pictured, the company's rendering of its cell-squeezing therapeutic process leveraging antigen presenting cells. Credit: SQZ Biotech

Cell-based immunotherapies, which often involve engineering cells to activate or suppress the immune system, have delivered some dramatic results to cancer patients with few other options. But the complex process of developing these therapies has limited a field that many believe could be a powerful new frontier in medicine.

Using a proprietary platform and an unconventional approach, startup SQZ Biotech is trying to expand immunotherapy impact by simplifying the process of engineering immune cells, thus unlocking a slew of new applications for the technology.

SQZ co-founder and CEO Armon Sharei SM '13 Ph.D. '13 says his company leverages a simple process—squeezing cells so they can be penetrated by specific molecules—to engineer a broader suite of cell functions than has been possible with the gene therapy approaches that have attracted the bulk of the investments in the field.

In the middle of next year, backed by over $100 million in funding and a collaboration with Roche that could net SQZ over $1 billion in drug development milestone payments, the startup is aiming to begin clinical trials on a treatment targeting human papillomavirus (HPV)-positive tumors. The company's next potential therapy is aimed at autoimmune diseases including Type 1 diabetes.

Clinical trials will be the true test for a technology that Sharei believes can have a life-altering impact across a variety disease types.

"There's many things SQZ can do," Sharei says. "We think [these two clinical programs] are just the beginning."

A novel approach

CAR T-cell therapies were approved by the U.S. Food and Drug Administration in 2017. They work by extracting a patient's T cells, known as the soldiers of the immune system, and genetically engineering them to attack cancer cells. The engineered T cells are then injected back into the patient. The process has demonstrated the remarkable potential of immunotherapy, but it is still being refined, has certain limitations, and can be prohibitively expensive.

SQZ's lead programs avoid genetic engineering to modulate long-term immune responses. The company's current focus in oncology is on a broad class of cells known as antigen presenting cells, or APCs, which Sharei describes as the "generals of the immune system." APCs can instruct a patient's T cells to attack by presenting the right antigens on their surface in a function of the immune system that occurs naturally.

Engineering APCs to drive specific immune responses has been a struggle for researchers to date, but SQZ has shown that their platform offers a simple, scalable way to tackle the issue. The platform works by squeezing a patient's immune cells through narrow channels on a microfluidic chip, making the cell membranes temporarily open up. Tumor-associated antigens are inserted into the cells and then naturally present on the cell's surface, creating an APC. The engineered APCs can then be given back to the patient, where they can instruct the patient's T cells as they naturally would, offering a relatively simple way to train T cells to attack .

Conversely, when SQZ's technology is used to target autoimmune diseases, can be squeezed and manipulated to suppress an immune response, which Sharei says could lead to an innovative approach to treating chronic auto-immune diseases such as Type 1 diabetes.

An unexpected breakthrough

The technology behind SQZ was discovered out of exasperation as much as innovation. It began as a research project in the lab of Klavs Jensen, the Warren K. Lewis Professor of Chemical Engineering and a professor of materials science and engineering at MIT.

For over three years, researchers on the project attempted to shoot materials into cells using a microfluidic device and a jet. The cells proved to be difficult to penetrate, often deflecting away from the jet's stream, so the team started forcing the cells toward the jet by constricting the cells through smaller channels within the chip. Eventually the project started to yield limited, often uncontrollable, results.

"It was a rough project," remembers Sharei, who joined the project as a Ph.D. candidate when it was roughly two years old, while being co-advised by Jensen and Robert Langer, the David H. Koch Institute Professor. "There was quite a while when nothing was happening. We kept banging our head against the wall with the jet technique."

One day the team decided to run the cells through the system without the jet and found that biomaterials in the fluid still entered the . That's when they realized that constricting, or squeezing, the cell was opening up holes in the cell membranes.

The discovery set off a string of experiments to improve the process. In 2013, Sharei, Jensen, and Langer founded SQZ Biotech to share the cell squeezing technology with other research groups. But those collaborations didn't produce the kind of groundbreaking experiments Sharei and his team were hoping for.

"Companies and academics weren't really using SQZ for the new things it could do," Sharei says. "They were using it for the things they could already do, just to do them better. That wasn't going to have the game changing impact we envisioned for it."

So SQZ pivoted from providing a lab tool to developing new therapies. Sharei, whose undergraduate work in organic electronics had made him an unlikely participant in the original research project to begin with, found himself with his first full-time job running a company with a unique strategy.

"At the time, the cell therapy industry was very focused on CAR T-cell therapy and gene editing," Sharei says. "We thought there were much more powerful and simple concepts to implement [with SQZ], and you could hit a lot more diseases. This was an initially difficult message to convey to the field."

But the broader perception of SQZ changed overnight when the startup signed a partnership with Roche toward the end of 2015, which marked Roche's first investment in cell-based immunotherapies. Recently, after nearly three years of encouraging preclinical research, Roche announced a dramatic expansion of that partnership, to include more types of APCs in the upcoming . The deal gives SQZ $125 million in upfront payments and near-term milestones. On top of that, SQZ may receive development milestone payments of over $1 billion from the pharmaceutical giant. The collaboration also stipulates the two companies could share certain commercial rights to approved products in the future.

The deal gives SQZ some spending power as it tries to strike a balance among pursuing research initiatives internally, partnering with other companies, and granting licenses to outside research groups.

For Sharei, the researcher-turned-CEO, the goal is finding the right path to turn SQZ's potential into treatments that maximize impact for patients.

"The long-term vision is a company that's creating many different cell-based therapeutics that have an impact across different disease areas," Sharei says. "But getting there is all about seeing how these [early trials] do. And as those start to show proof, we can expand into different disease areas as well as broaden the footprint of our early trials."

Explore further: Microfluidic cell-squeezing device opens new possibilities for cell-based vaccines

Related Stories

Microfluidic cell-squeezing device opens new possibilities for cell-based vaccines

May 22, 2015
MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune system's B cells, providing a new approach to developing and implementing antigen-presenting ...

Compressing cells allows delivery of new fluorescent tags to track proteins in living cells

February 2, 2016
Tagging proteins with a fluorescent label such as green fluorescent protein (GFP) is currently the best way to track specific molecules inside a living cell. However, while this approach has yielded many significant discoveries, ...

How an idea from a lab may change cancer treatments

October 18, 2018
In recent years, researchers have begun to fight cancer by genetically engineering a patient's own immune system to target the disease. Quad Technologies, a company that grew out of a Northeastern research lab, has been developing ...

A simple blood test provides personalised therapy for cancer patients

September 6, 2018
Researchers have developed a simple blood test that can select cancer patients where therapies that use the body's own immune system (immunotherapies) are more likely to be effective.

CAR-T therapy works for some blood cancers, but can we make it work for brain tumours?

July 26, 2018
A powerful new anti-cancer therapy, called CAR-T, has shown great promise in treating blood cancers. Last year, the Food and Drug Administration approved the treatment for acute lymphoblastic leukaemia, and the results have ...

New system developed that can switch on immune cells to attack cancer cells

December 7, 2016
Researchers have developed an artificial structure that mimics the cell membrane, which can switch on immune cells to attack and destroy a designated target. This method has potential to be used as a future cancer immunotherapy ...

Recommended for you

To resolve inflammation, location matters

November 19, 2018
Health conditions that involve inflammation run the gamut, from multiple sclerosis and lupus to arthritis, diabetes, and cancer. While inflammation can serve as a normal response to help the body deal with injury or infection, ...

New insights into how an ordinary stem cell becomes a powerful immune agent

November 19, 2018
How do individual developing cells choose and commit to their "identity"—to become, for example, an immune cell, or a muscle cell, or a neuron?

New inflammation inhibitor discovered

November 16, 2018
A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action. By inhibiting a certain protein, the researchers were able ...

Pets can double as asthma antidote

November 16, 2018
(HealthDay)—The "hygiene hypothesis" holds that early exposure to a variety of microorganisms may decrease the risk for chronic inflammatory diseases, like asthma.

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

Defense against intestinal infection in organism is affected by prostaglandin E2

November 15, 2018
The treatment of intestinal infections caused by some strains of the bacterium Escherichia coli, present in unsanitized or contaminated foods, may have a new ally.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.